NSCLC

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against the standard drug pembrolizumab for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. The trial was stopped early, but researchers measured how long patients…

This study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a potent chemotherapy directly to cancer cells. …

This study tested two experimental drugs, AK119 and AK112, with or without chemotherapy, in 59 adults with advanced non-squamous lung cancer that has a specific EGFR gene change and stopped responding to standard targeted therapy. The goal was to see if the combination is safe an…

This study monitored drug levels in the blood of 80 patients with advanced non-small cell lung cancer who were receiving pembrolizumab (immunotherapy) alone or with chemotherapy. Researchers wanted to see if drug levels were linked to how well the cancer responded or if side effe…

This study looked at 21 adults with advanced lung cancer to see if a blood test (liquid biopsy) could detect EGFR gene mutations as accurately as a standard tumor tissue biopsy. The goal was to find a less invasive way to guide treatment decisions. The study was terminated early,…

This study tested a new way of combining PET and MRI scans to see how well they can map differences within lung cancer tumors. Researchers wanted to know if different doctors reading the scans would get the same results. The study included 11 adults with advanced non-small cell l…